Novel therapeutic strategies targeting vascular endothelium in essential hypertension

Expert Opinion on Investigational Drugs

Volumn 19, Issue 11, 2010, Pages 1395-1412

  Tousoulis, Dimitris ^a   Papageorgiou, Nikolaos ^a   Androulakis, Emmanouil ^a   Paroutoglou, Kiriaki ^a   Stefanadis, Christodoulos ^a  

^a UNIVERSITY OF ATHENS MEDICAL SCHOOL   (Greece)

Author keywords

angiotensin; blood pressure; endothelium; hypertension; nitric oxide; renin

Indexed keywords

2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL] 5 MORPHOLINO 4,6 PYRIMIDINEDIAMINE; 4 [[4 CARBOXYBUTYL[2 [(4 PHENETHYLBENZYL)OXY]PHENETHYL]AMINO]METHYL]BENZOIC ACID; 4 AMINO 5 CYCLOPROPYL 2 [1 (2 FLUOROBENZYL) 1H PYRAZOLO[3,4 B]PYRIDIN 3 YL]PYRIMIDINE; ACETYLCYSTEINE; ALISKIREN; ALPHA TOCOPHEROL; AMLODIPINE; ANTIHYPERTENSIVE AGENT; ANTIOXIDANT; ARGININE; ASCORBIC ACID; ATENOLOL; ATORVASTATIN; BENDROFLUMETHIAZIDE; CARVEDILOL; COLECALCIFEROL; GLYCERYL TRINITRATE; HMR 1766; LA 419; NAPROXCINOD; NCX 899; NEBIVOLOL; NITRONAPROXEN; PERINDOPRIL; PLACEBO; POLYPHENOL DERIVATIVE; QUINAPRIL; RAMIPRIL; REACTIVE OXYGEN METABOLITE; SILDENAFIL; TELMISARTAN; TETRAHYDROBIOPTERIN; UNCLASSIFIED DRUG; UNINDEXED DRUG; VALSARTAN;

ANTIHYPERTENSIVE ACTIVITY; ATHEROSCLEROSIS; CLINICAL TRIAL; DIASTOLIC BLOOD PRESSURE; DISEASE ASSOCIATION; ENDOTHELIAL DYSFUNCTION; ESSENTIAL HYPERTENSION; HEART PROTECTION; HUMAN; NONHUMAN; RENIN ANGIOTENSIN ALDOSTERONE SYSTEM; REVIEW; SPONTANEOUSLY HYPERTENSIVE RAT; SYSTOLIC BLOOD PRESSURE; VASCULAR ENDOTHELIUM;

ANIMALS; ANTIHYPERTENSIVE AGENTS; ENDOTHELIUM, VASCULAR; HUMANS; HYPERTENSION;

EID: 77958466526     PISSN: 13543784     EISSN: None     Source Type: Journal    
DOI: 10.1517/13543784.2010.522989     Document Type: Review

References (169)

1. Messerli FH, Williams B, Ritz E. Essential hypertension. Lancet 2007;370:591-603
2. Vedanthan R, Fuster V. Disease prevention: the moving target of global cardiovascular health. Nat Rev Cardiol 2009;6:327-8
3. Kearney PM, Whelton M, Reynolds K, et al. Global burden of hypertension: analysis of worldwide data. Lancet 2005;365:217-23
4. Davignon J, Ganz P. Role of endothelial dysfunction in atherosclerosis. Circulation 2004;109(Suppl 1):III 27-32
5. Kiowski W. Endothelial dysfunction in hypertension. Clin Exp Hypertens 1999;21:635-46
6. Rizzoni D, Aqabiti-Rosei E. Endothelial factors and microvascular hypertensive disease. J Cardiovasc Pharmacol 2001;38(Suppl 2):S15-18
7. Versari D, Daghini E, Virdis A, et al. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol 2009;157:527-36
8. Hadi HA, Carr CS, Al Suwaidi J. Endothelial dysfunction: cardiovascular risk factors, therapy, and outcome. Vasc Health Risk Manag 2005;1:183-98
9. Dobarro D, Gomez-Rubin MC, Sanchez-Recalde A, et al. Current pharmacological approach to restore endothelial dysfunction. Cardiovasc Hematol Agents Med Chem 2007;7:212-22
10. Ludmer PL, Selwyn AP, Shook TL, et al. Paradoxical vasoconstriction induced by acetylcholine in atherosclerotic coronary arteries. N Engl J Med 1986;315:1046-51
11. Seiler C, Hess OM, Buechi M, et al. Coronary vasomotor response to acetylcholine relate to risk factor for coronary artery disease. Circulation 1990;81:491-7
12. Viles-Gonzalez JF, Anand SX, Valdiviezo C, et al. Update in atherothrombotic disease. Mt Sinai J Med 2004;71:197-208
13. Sambola A, Fuster V, Badimon JJ. Role of coronary risk factors in blood thrombogenicity and acute coronary syndromes. Rev Esp Cardiol 2003;56:1001-9
14. Tousoulis D, Davies G, Crake T, et al. Acetylcholine and endothelial function. Circulation 1998;98:1587-90
15. Tousoulis D, Davies G, Lefroy DC, et al. Variable coronary vasomotor responses to acetylcholine in patients with normal coronary arteriograms: evidence for localised endothelial dysfunction. Heart 1996;75:261-6
16. Tousoulis D, Antoniades C, Stefanadis C. Evaluating endothelial function in humans: a guide to invasive and non-invasive techniques. Heart 2005;91:553-8
17. Higashi Y, Sasaki S, Nakagawa K, et al. Effect of the angiotensin-converting enzyme inhibitor imidapril on reactive hyperemia in patients with essential hypertension: relationship between treatment periods and resistance artery endothelial function. J Am Coll Cardiol 2001;37:863-70
18. Deanfield J, Donald A, Ferri C, et al. Endothelial function and dysfunction. Part I: methodological issues for assessment in the different vascular beds: a statement by the Working Group on Endothelin and Endothelial Factors of the European Society of Hypertension. J Hypertens 2005;23:7-17 (Pubitemid 40128972)
19. Moens AL, Goovaerts I, Claeys MJ, Vrints CJ. Flow-mediated vasodilation: a diagnostic instrument, or an experimental tool? Chest 2005;127:2254-63
20. Corretti MC, Anderson TJ, Benjamin EJ, et al. Guidelines for the ultrasound assessment of endothelial-dependent flow-mediated vasodilation of the brachial artery: a report of the International Brachial Artery Reactivity Task Force. J Am Coll Cardiol 2002;39:257-65
21. Ghiadoni L, Versari D, Giannarelli C, et al. Non-invasive diagnostic tools for investigating endothelial dysfunction. Curr Pharm Des 2008;14:3715-22
22. Celermajer DS, Sorensen KE, Gooch VM, et al. Non-invasive detection of endothelial dysfunction in children and adults at risk of atherosclerosis. Lancet 1992;340:1111-15
23. Antoniades C, Shirodaria C, Crabtree M, et al. Altered plasma versus vascular biopterins in human atherosclerosis reveal relationships between endothelial nitric oxide synthase coupling, endothelial function, and inflammation. Circulation 2007;116:2851-9
24. Esper RJ, Nordaby RA, Vilarino JO, et al. Endothelial dysfunction: a comprehensive appraisal. Cardiovasc Diabetol 2006;5:4
25. Bonetti PO, Lerman LO, Lerman A. Endothelial dysfunction: a marker of atherosclerotic risk. Arterioscler Thromb Vasc Biol 2003;23:168-75
26. Schulz E, Jansen T, Wenzel P, et al. Nitric oxide, tetrahydropterin, oxidative stress, and endothelial dysfunction in hypertension. Antioxid Redox Signal 2008;10:1115-26
27. Androulakis ES, Tousoulis D, Papageorgiou N, et al. Essential hypertension: is there a role for inflammatory mechanisms? Cardiol Rev 2009;17:216-21
28. Schmidt TS, Alp NJ. Mechanisms for the role of tetrahydrobiopterin in endothelial function and vascular disease. Clin Sci (Lond) 2007;113:47-63
29. Creager MA, Gallagher SJ, Girerd XJ, et al. L-Arginine improves endothelium-dependent vasodilation in hypercholesterolemic humans. J Clin Invest 1992;90:1248-53
30. Huang PL, Huang Z, Mashimo H, et al. Hypertension in mice lacking the gene for endothelial nitric oxide synthase. Nature 1995;377:239-42
31. Touyz RM. Reactive oxygen species in vascular biology: role in arterial hypertension. Expert Rev Cardiovasc Ther 2003;1:99-106
32. Schulman IH, Zhou MS, Raij L. Interaction between nitric oxide and angiotensin II in the endothelium: role in atherosclerosis and hypertension. J Hypertens 2006;24:S45-50
33. Taddei S, Virdis A, Mattei P, et al. Defective L-arginine-nitric oxide pathway in offspring of essential hypertensive patients. Circulation 1996;94:1298-303
34. Schlaich MP, Parnell MM, Ahlers BA, et al. Impaired L-arginine transport and endothelial function in hypertensive and genetically predisposed normotensive subjects. Circulation 2004;110:3680-6
35. Yang Z, Venardos K, Jones E, et al. Identification of a novel polymorphism in the 3'UTR of the L-arginine transporter gene SLC7A1: contribution to hypertension and endothelial dysfunction. Circulation 2007;115:1269-74
36. Cosentino F, Barker JE, Brand MP, et al. Reactive oxygen species mediate endothelium-dependent relaxations in tetrahydrobiopterin-deficient mice. Arterioscler Thromb Vasc Biol 2001;21:496-502
37. Versari D, Daghini E, Virdis A, et al. Endothelium-dependent contractions and endothelial dysfunction in human hypertension. Br J Pharmacol 2009;157:527-36
38. Landmesser U, Hornig B, Drexler H. Endothelial function: a critical determinant in atherosclerosis? Circulation 2004;109(Suppl 1):II 27-33
39. Schafer A, Bauersachs J. Endothelial dysfunction, impaired endogenous platelet inhibition and platelet activation in diabetes and atherosclerosis. Curr Vasc Pharmacol 2008;6:52-60
40. Rudic RD, Sessa WC. Nitric oxide in endothelial dysfunction and vascular remodeling: clinical correlates and experimental links. Am J Hum Genet 1999;64:673-7
41. Correia ML, Haynes WG. Arterial compliance and endothelial function. Curr Diab Rep 2007;7:269-75
42. Haynes WG, Hand MF, Johnstone HA, et al. Direct and sympathetically mediated venoconstriction in essential hypertension. Enhanced responses to endothelin-1. J Clin Invest 1994;94:1359-64
43. Chalon S, Moreno H Jr, Hoffman BB, Blaschke TF. Angiotensin-converting enzyme inhibition improves venous endothelial dysfunction in chronic smokers. Clin Pharmacol Ther 1999;65:295-303
44. Rubira MC, Consolim-Colombo FM, Rabelo ER, et al. Venous or arterial endothelium evaluation for early cardiovascular dysfunction in hypertensive patients? J Clin Hypertens (Greenwich) 2007;9:859-65
45. De Berrazueta JR, Gonzalez JP, de Mier I, et al. Vasodilatory action of loop diuretics: a plethysmography study of endothelial function in forearm arteries and dorsal hand veins in hypertensive patients and controls. J Cardiovasc Pharmacol 2007;49:90-5
46. Le Brocq M, Leslie SJ, Milliken P, Megson IL. Endothelial dysfunction: from molecular mechanisms to measurement, clinical implications, and therapeutic opportunities. Antioxid Redox Signal 2008;9:1631-74
47. Munzel T, Sinning C, Post F, et al. Pathophysiology, diagnosis and prognostic implications of endothelial dysfunction. Ann Med 2009;40:180-96
48. Martin BJ, Anderson TJ. Risk prediction in cardiovascular disease: the prognostic significance of endothelial dysfunction. Can J Cardiol 2009;25:15A-20A
49. Shimbo D, Grahame-Clarke C, Miyake Y, et al. The association between endothelial dysfunction and cardiovascular outcomes in a population-based multi-ethnic cohort. Atherosclerosis 2007;192:197-203
50. Perticone F, Ceravolo R, Pujia A, et al. Prognostic significance of endothelial dysfunction in hypertensive patients. Circulation 2001;104:191-6
51. John S, Schmieder RE. Potential mechanisms of impaired endothelial function in arterial hypertension and hypercholesterolemia. Curr Hypertens Rep 2003;5:199-207
52. Rocha VZ, Libby P. Obesity, inflammation, and atherosclerosis. Nat Rev Cardiol 2009;6:399-409
53. Viles-Gonzalez JF, Fuster V, Corti R, Badimon JJ. Emerging importance of HDL cholesterol in developing high-risk coronary plaques in acute coronary syndromes. Curr Opin Cardiol 2003;18:286-94
54. Juonala M, Viikari JS, Laitinen T, et al. Interrelations between brachial endothelial function and carotid intima-media thickness in young adults: the cardiovascular risk in young Finns study. Circulation 2004;110:2918-23
55. Laurent S, Cockcroft J, Van Bortel L, et al. European Network for Non-invasive Investigation of Large Arteries. Expert consensus document on arterial stiffness: methodological issues and clinical applications. Eur Heart J 2006;27:2588-605
56. Wallace SM, Yasmin, McEniery CM, et al. Isolated systolic hypertension is characterized by increased aortic stiffness and endothelial dysfunction. Hypertension 2007;50:228-33
57. McEniery CM, Wallace S, Mackenzie IS, et al. Endothelial function is associated with pulse pressure, pulse wave velocity, and augmentation index in healthy humans. Hypertension 2006;48:602-8
58. Marcus ML, Harrison DG, Chilian WM, et al. Alterations in the coronary circulation in hypertrophied ventricles. Circulation 1987;75:I19-25
59. Brush JE Jr, Cannon RO III, Schenke WH, et al. Angina due to coronary microvascular disease in hypertensive patients without left ventricular hypertrophy. N Engl J Med 1988;319:1302-7
60. Treasure CB, Klein JL, Vita JA, et al. Hypertension and left ventricular hypertrophy are associated with impaired endothelium-mediated relaxation in human coronary resistance vessels. Circulation 1993;87:86-93
61. Camici PG, Crea F. Coronary microvascular dysfunction. N Engl J Med 2007;356:830-40
62. Zizek B, Poredos P. Increased left ventricular mass and diastolic dysfunction are associated with endothelial dysfunction in normotensive offspring of subjects with essential hypertension. Blood Press 2007;16:36-44
63. Ruilope LM, van Veldhuisen DJ, Ritz E, Luscher TF. Renal function: the Cinderella of cardiovascular risk profile. J Am Coll Cardiol 2001;38:1782-7
64. van der Zee S, Baber U, Elmariah S, et al. Cardiovascular risk factors in patients with chronic kidney disease. Nat Rev Cardiol 2009;6:580-9
65. Perticone F, Maio R, Tripepi G, Zoccali C. Endothelial dysfunction and mild renal insufficiency in essential hypertension. Circulation 2004;110:821-5
66. Perticone F, Maio R, Sciacqua A, et al. Endothelial dysfunction and C-reactive protein are risk factors for diabetes in essential hypertension. Diabetes 2008;57:167-71
67. Kaplan NM. Combination therapy for hypertension. Nat Rev Cardiol 2009;6:270-1
68. Landmesser U, Drexler H. Endothelial function and hypertension. Curr Opin Cardiol 2007;22:316-20
69. Siasos G, Tousoulis D, Vlachopoulos C, et al. The impact of oral L-arginine supplementation on acute smoking-induced endothelial injury and arterial performance. Am J Hypertens 2009;22:586-92
70. Tousoulis D, Davies GJ, Tentolouris C, et al. Effects of L-arginine on flow mediated dilatation induced by atrial pacing in diseased epicardial coronary arteries. Heart 2003;89:531-4
71. Siasos G, Tousoulis D, Vlachopoulos C, et al. Short-term treatment with L-arginine prevents the smoking-induced impairment of endothelial function and vascular elastic properties in young individuals. Int J Cardiol 2008;126:394-9
72. Tousoulis D, Antoniades C, Tentolouris C, et al. L-Arginine in cardiovascular disease: dream or reality? Vasc Med 2002;7:203-11
73. Siasos G, Tousoulis D, Antoniades C, et al. L-Arginine, the substrate for NO synthesis: an alternative treatment for premature atherosclerosis? Int J Cardiol 2007;116:300-8
74. Cavanal Mde F, Gomes GN, Forti AL, et al. The influence of L-arginine on blood pressure, vascular nitric oxide and renal morphometry in the offspring from diabetic mothers. Pediatr Res 2007;62:145-50
75. Zhou MS, Kosaka H, Tian RX, et al. L-Arginine improves endothelial function in renal artery of hypertensive Dahl rats. J Hypertens 2001;19:421-9
76. Goret L, Tanguy S, Guiraud I, et al. Acute administration of L-arginine restores nitric oxide-mediated relaxation in isolated pulmonary arteries from pulmonary hypertensive exercise trained rats. Eur J Pharmacol 2008;581:148-56
77. Lekakis JP, Papathanassiou S, Papaioannou TG, et al. Oral L-arginine improves endothelial dysfunction in patients with essential hypertension. Int J Cardiol 2002;86:317-23
78. Tousoulis D, Antoniades C, Koumallos N, et al. Novel therapies targeting vascular endothelium. Endothelium 2006;13:411-21
79. Podjarny E, Benchetrit S, Rathaus M, et al. Effect of tetrahydrobiopterin on blood pressure in rats after subtotal nephrectomy. Nephron Physiol 2003;94:6-9
80. Higashi Y, Sasaki S, Nakagawa K, et al. Tetrahydrobiopterin enhances forearm vascular response to acetylcholine in both normotensive and hypertensive individuals. Am J Hypertens 2002;15:326-32
81. Porkert M, Sher S, Reddy U, et al. Tetrahydrobiopterin: a novel antihypertensive therapy. J Hum Hypertens 2008;22:401-7
82. Kase H, Hashikabe Y, Uchida K, et al. Supplementation with tetrahydrobiopterin prevents the cardiovascular effects of angiotensin II-induced oxidative and nitrosative stress. J Hypertens 2005;23:1375-82
83. Paravicini TM, Touyz RM. NADPH oxidases, reactive oxygen species, and hypertension: clinical implications and therapeutic possibilities. Diabetes Care 2008;31(Suppl 2):S170-80
84. Plantinga Y, Ghiadoni L, Magagna A, et al. Supplementation with vitamins C and E improves arterial stiffness and endothelial function in essential hypertensive patients. Am J Hypertens 2007;20:392-7
85. Schneider MP, Delles C, Schmidt BM, et al. Superoxide scavenging effects of N-acetylcysteine and vitamin C in subjects with essential hypertension. Am J Hypertens 2005;18:1111-17
86. Forstermann U, Munzel T. Endothelial nitric oxide synthase in vascular disease: from marvel to menace. Circulation 2006;113:1708-14
87. Wong MS, Delansorne R, Man RY, Vanhoutte PM. Vitamin D derivatives acutely reduce endothelium-dependent contractions in the aorta of the spontaneously hypertensive rat. Am J Physiol Heart Circ Physiol 2008;295:H289-96
88. Tousoulis D, Antoniades C, Tentolouris C, et al. Effects of combined administration of vitamins C and E on reactive hyperemia and inflammatory process in chronic smokers. Atherosclerosis 2003;170:261-7
89. Antoniades C, Tousoulis D, Tentolouris C, et al. Effects of antioxidant vitamins C and E on endothelial function and thrombosis/fibrinolysis system in smokers. Thromb Haemost 2003;89:990-5
90. Tousoulis D, Xenakis C, Tentolouris C, et al. Effects of vitamin C on intracoronary L-arginine dependent coronary vasodilatation in patients with stable angina. Heart 2005;91:1319-23
91. Houston MC. The role of cellular micronutrient analysis, nutraceuticals, vitamins, antioxidants and minerals in the prevention and treatment of hypertension and cardiovascular disease. Ther Adv Cardiovasc Dis 2010;4:165-83
92. Briasoulis A, Tousoulis D, Antoniades C, Stefanadis C. The oxidative stress menace to coronary vasculature: any place for antioxidants? Curr Pharm Des 2009;15:3078-90
93. Kim MK, Sasaki S, Sasazuki S, et al. Lack of long-term effect of vitamin C supplementation on blood pressure. Hypertension 2002;40:797-803
94. Versari D, Daghini E, Rodriguez-Porcel M, et al. Chronic antioxidant supplementation impairs coronary endothelial function and myocardial perfusion in normal pigs. Hypertension 2006;47:475-81
95. Tousoulis D, Bouras G, Antoniades C, et al. The activation of endothelin-1 pathway during methionine-induced homocysteinemia mediates endothelial dysfunction in hypertensive individuals. J Hypertens 2010;28:925-30
96. Tousoulis D, Antoniades C, Vasiliadou C, et al. Effects of atorvastatin and vitamin C on forearm hyperaemic blood flow, asymmentrical dimethylarginine levels and the inflammatory process in patients with type 2 diabetes mellitus. Heart 2007;93:244-6
97. Tousoulis D, Antoniades C, Vassiliadou C, et al. Effects of combined administration of low dose atorvastatin and vitamin E on inflammatory markers and endothelial function in patients with heart failure. Eur J Heart Fail 2005;7:1126-32
98. Lopez-Sepulveda R, Jimenez R, Romero M, et al. Wine polyphenols improve endothelial function in large vessels of female spontaneously hypertensive rats. Hypertension 2008;51:1088-95
99. Sarr M, Chataigneau M, Martins S, et al. Red wine polyphenols prevent angiotensin II-induced hypertension and endothelial dysfunction in rats: role of NADPH oxidase. Cardiovasc Res 2006;71:794-802
100. Basu A, Lucas EA. Mechanisms and effects of green tea on cardiovascular health. Nutr Rev 2007;65:361-75
101. Alexopoulos N, Vlachopoulos C, Aznaouridis K, et al. The acute effect of green tea consumption on endothelial function in healthy individuals. Eur J Cardiovasc Prev Rehabil 2008;15:300-5
102. Antonello M, Montemurro D, Bolognesi M, et al. Prevention of hypertension, cardiovascular damage and endothelial dysfunction with green tea extracts. Am J Hypertens 2007;20:1321-8
103. Kristek F. Long-term administration of L-arginine did not influence blood pressure, heart rate, cardiac hypertrophy or arterial wall thickness of spontaneously hypertensive rats. Exp Physiol 1998;83:595-603
104. Roberts JM, Myatt L, Spong CY, et al. Vitamins C and E to prevent complications of pregnancy-associated hypertension. N Engl J Med 2001;362:1282-91
105. Maffei A, Lembo G. Nitric oxide mechanisms of nebivolol. Ther Adv Cardiovasc Dis 2009;3:317-27
106. Munzel T, Gori T. Nebivolol: the somewhat-different beta-adrenergic receptor blocker. J Am Coll Cardiol 2009;54:1491-9
107. Merchant N, Searles CD, Pandian A, et al. Nebivolol in high-risk, obese African Americans with stage 1 hypertension: effects on blood pressure, vascular compliance, and endothelial function. J Clin Hypertens (Greenwich) 2009;11:720-5
108. Pasini AF, Garbin U, Stranieri C, et al. Nebivolol treatment reduces serum levels of asymmetric dimethylarginine and improves endothelial dysfunction in essential hypertensive patients. Am J Hypertens 2008;21:1251-7
109. Korkmaz H, Karaca I, Koc M, et al. Early effects of treatment with nebivolol and quinapril on endothelial function in patients with hypertension. Endothelium 2008;15:149-55
110. Tzemos N, Lim PO, MacDonald TM. Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study. Circulation 2001;104:511-4
111. Kobusiak-Prokopowicz M, Jolda-Mydlowska B, Zubkiewicz A, et al. Impact of nebivolol on levels of serum nitric oxide, plasma von Willebrand factor and exercise stress testing parameters in hypertensive and ischemic heart disease patients. Cardiol J 2008;15:162-8
112. Aqabiti-Rosei E, Porteri E, Rizzoni D. Arterial stiffness, hypertension, and rational use of nebivolol. Vasc Health Risk Manag 2009;5:353-60
113. Okuyama CE, Mendes GD, Faro R, et al. Pharmacokinetics and pharmacodynamics of a nitric oxide-releasing derivative of enalapril in male beagles. Clin Exp Pharmacol Physiol 2007;34:290-5
114. Iwanaga Y, Gu Y, Dieterle T, et al. A nitric oxide-releasing derivative of enalapril, NCX 899, prevents progressive cardiac dysfunction and remodeling in hamsters with heart failure. FASEB J 2004;18:587-8
115. White WB, Schnitzer TJ, Fleming R, et al. Effects of the cyclooxygenase inhibiting nitric oxide donator naproxcinod versus naproxen on systemic blood pressure in patients with osteoarthritis. Am J Cardiol 2009;104:840-5
116. White W, Schnitzer T, Dijian J, et al. The nitric oxide donator naproxcinod has blood pressure effects similar to placebo in patients on renin-angiotensin system blockers. J Hypertens 2010;28:e441
117. Miglietta D, Poggi A, Vergani B, et al. Naproxcinod counterbalances vasoconstriction due to Cox inhibition in human arteries with endothelial dysfunction. J Hypertens 2010;28:e125
118. Ruiz-Hurtado G, Fernandez-Velasco M, Mourelle M, Delgado C. LA419, a novel nitric oxide donor, prevents pathological cardiac remodeling in pressure-overloaded rats via endothelial nitric oxide synthase pathway regulation. Hypertension 2007;50:1049-56
119. Priviero FB, Zemse SM, Teixeira CE, Webb RC. Oxidative stress impairs vasorelaxation induced by the soluble guanylyl cyclase activator BAY 41-2272 in spontaneously hypertensive rats. Am J Hypertens 2009;22:493-9
120. Briones AM, Padilha AS, Cogolludo AL, et al. Activation of BKCa channels by nitric oxide prevents coronary artery endothelial dysfunction in ouabain-induced hypertensive rats. J Hypertens 2009;27:83-91
121. Teixeira CE, Priviero FB, Todd J Jr, Webb RC. Vasorelaxing effect of BAY 41-2272 in rat basilar artery: involvement of cGMP-dependent and independent mechanisms. Hypertension 2006;47:596-602
122. Dumitrascu R, Weissmann N, Ghofrani HA, et al. Activation of soluble guanylate cyclase reverses experimental pulmonary hypertension and vascular remodeling. Circulation 2006;113:286-95
123. Stasch JP, Alonso-Alija C, Apeler H, et al. Pharmacological actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vitro studies. Br J Pharmacol 2002;135:333-43
124. Stasch JP, Dembowsky K, Perzborn E, Stahl E. Cardiovascular actions of a novel NO-independent guanylyl cyclase stimulator, BAY 41-8543: in vivo studies. Br J Pharmacol 2002;135:344-55
125. Evgenov OV, Kohane DS, Bloch KD, et al. Inhaled agonists of soluble guanylate cyclase induce selective pulmonary vasodilation. Am J Respir Crit Care Med 2007;176:1138-45
126. Radovits T, Korkmaz S, Miesel-Groschel C, et al. Pre-conditioning with the soluble guanylate cyclase activator Cinaciguat reduces ischaemia-reperfusion injury after cardiopulmonary bypass. Eur J Cardiothorac Surg 2010: published online 29 June 2010, doi:10.1016/j.ejcts.2010.05.025
127. Stasch JP, Schmidt PM, Nedvetsky PI, et al. Targeting the heme-oxidized nitric oxide receptor for selective vasodilatation of diseased blood vessels. J Clin Invest 2006;116:2552-61
128. Chester M, Tourneux P, Seedorf G, et al. Cinaciguat, a soluble guanylate cyclase activator, causes potent and sustained pulmonary vasodilation in the ovine fetus. Am J Physiol Lung Cell Mol Physiol 2009;297:L318-25
129. Schafer A, Fraccarollo D, Werner L, Bauersachs J. Guanylyl cyclase activator ataciguat improves vascular function and reduces platelet activation in heart failure. Pharmacol Res 2010: published online 22 June 2010, doi:10.1016/j.phrs.2010.06.008
130. Kasseckert SA, Schafer C, Kluger A, et al. Stimulation of cGMP signalling protects coronary endothelium against reperfusion-induced intercellular gap formation. Cardiovasc Res 2009;83:381-7
131. Zhou Z, Pyriochou A, Kotanidou A, et al. Soluble guanylyl cyclase activation by HMR-1766 (ataciguat) in cells exposed to oxidative stress. Am J Physiol Heart Circ Physiol 2008;295:H1763-71
132. Montani D, Chaumais MC, Savale L, et al. Phosphodiesterase type 5 inhibitors in pulmonary arterial hypertension. Adv Ther 2009;26:813-25
133. Yugar-Toledo JC, Ferreira-Melo SE, Consolim-Colombo FM, et al. Cyclic guanosine monophosphate phosphodiesterase-5 inhibitor promotes an endothelium NO-dependent-like vasodilation in patients with refractory hypertension. Nitric Oxide 2007;16:315-21
134. Yaguas K, Bautista R, Quiroz Y, et al. Chronic sildenafil treatment corrects endothelial dysfunction and improves hypertension. Am J Nephrol 2010;31:283-91
135. Attina TM, Malatino LS, Maxwell SR, et al. Phosphodiesterase type 5 inhibition reverses impaired forearm exercise-induced vasodilatation in hypertensive patients. J Hypertens 2008;26:501-7
136. Rossoni G, Manfredi B, De Gennaro Colonna V, et al. Sildenafil reduces L-NAME-induced severe hypertension and worsening of myocardial ischaemia-reperfusion damage in the rat. Br J Pharmacol 2007;150:567-76
137. Ferreira-Melo SE, Yugar-Toledo JC, Coelho OR, et al. Sildenafil reduces cardiovascular remodeling associated with hypertensive cardiomyopathy in NOS inhibitor-treated rats. Eur J Pharmacol 2006;542:141-7
138. Oliver JJ, Dear JW, Webb DJ. Clinical potential of combined organic nitrate and phosphodiesterase type 5 inhibitor in treatment-resistant hypertension. Hypertension 2010;56:62-7
139. Dussault S, Maingrette F, Menard C, et al. Sildenafil increases endothelial progenitor cell function and improves ischemia-induced neovascularization in hypercholesterolemic apolipoprotein E-deficient mice. Hypertension 2009;54:1043-9
140. Gur S, Kadowitz PJ, Gurkan L, et al. Chronic inhibition of nitric-oxide synthase induces hypertension and erectile dysfunction in the rat that is not reversed by sildenafil. BJU Int 2010;106:78-83
141. FalkJA, Philip KJ, Schwarz ER. The emergence of oral tadalafil as a once-daily treatment for pulmonary arterial hypertension. Vasc Health Risk Manag 2010;6:273-80
142. Sawamura F, Kato M, Fujita K, et al. Tadalafil, a long-acting inhibitor of PDE5, improves pulmonary hemodynamics and survival rate of monocrotaline-induced pulmonary artery hypertension in rats. J Pharmacol Sci 2009;111:235-43
143. Aversa A, Greco E, Bruzziches R, et al. Relationship between chronic tadalafil administration and improvement of endothelial function in men with erectile dysfunction: a pilot study. Int J Impot Res 2007;19:200-7
144. Bohm M. Angiotensin receptor blockers versus angiotensin-converting enzyme inhibitors: where do we stand now? Am J Cardiol 2007;100:38J-44J
145. Stefanadi E, Tousoulis D, Androulakis ES, et al. Inflammatory markers in essential hypertension: potential clinical implications. Curr Vasc Pharmacol 2010;8:509-16
146. Tousoulis D, Kourtellaris P, Antoniades C, et al. Effects of irbesartan and perindopril on forearm reactive hyperemia and inflammatory process, in normotensive patients with coronary artery disease. Int J Cardiol 2008;124:127-9
147. Brili S, Tousoulis D, Antoniades C, et al. Effects of ramipril on endothelial function and the expression of proinflammatory cytokines and adhesion molecules in young normotensive subjects with successfully repaired coarctation of aorta: a randomized cross-over study. J Am Coll Cardiol 2008;51:742-9
148. Ruilope LM, Redon J, Schmieder ER Cardiovascular risk reduction by reversing endothelial dysfunction: ARBs, ACE inhibitors, or both? Expectations from the ONTARGET Trial Programme. Vasc Health Risk Manag 2007;3:1-9
149. Vyssoulis GP, Tousoulis D, Antoniades C, et al. C. Alpha-1 Microglobulin as a new inflammatory marker in newly diagnosed hypertensive patients. Am J Hypertens 2007;20:1016-21
150. Ritt M, Ott C, Raff U, et al. Renal vascular endothelial function in hypertensive patients with type 2 diabetes mellitus. Am J Kidney Dis 2009;53:281-9
151. Grassi G, Quarti-Trevano F, Mancia G. Cardioprotective effects of telmisartan in uncomplicated and complicated hypertension. J Renin Angiotensin Aldosterone Syst 2008;9:66-74
152. Giugliano D, Marfella R, Acampora R, et al. Effects of perindopril and carvedilol on endothelium-dependent vascular functions in patients with diabetes and hypertension. Diabetes Care 1998;21:631-6
153. Tzemos N, Lim PO, Macdonald TM. Valsartan improves endothelial dysfunction in hypertension: a randomized, double-blind study. Cardiovasc Ther 2009;27:151-8
154. Athyros VG, Mikhailidis DP, Kakafika AI, et al. Angiotensin II reactivation and aldosterone escape phenomena in renin-angiotensin-aldosterone system blockade: is oral renin inhibition the solution? Expert Opin Pharmacother 2007;8:529-35
155. Brown MJ. Success and failure of vaccines against renin-angiotensin system components. Nat Rev Cardiol 2009;6:639-47
156. Rauch U, Osende JI, Chesebro JH, et al. Statins and cardiovascular diseases: the multiple effects of lipid-lowering therapy by statins. Atherosclerosis 2000;153:181-9
157. Stepien M, Banach M, Mikhailidis DP, et al. Role and significance of statins in the treatment of hypertensive patients. Curr Med Res Opin 2009;25:1995-2005
158. Milionis HJ, Liberopoulos EN, Elisaf MS, Mikhailidis DP. Analysis of antihypertensive effects of statins. Curr Hypertens Rep 2007;9:175-83
159. Sarkar K, Sihna AK, Mehta JL. The role of statins in endothelial dysfunction in hypertension. Curr Opin Cardiol 2006;21:316-21
160. Dilaveris P, Giannopoulos G, Riga M, et al. Beneficial effects of statins on endothelial dysfunction and vascular stiffness. Curr Vasc Pharmacol 2007;5:227-37
161. Pretnar-Oblak J, Sebestjen M, Sabovic M. Statin treatment improves cerebral more than systemic endothelial dysfunction in patients with arterial hypertension. Am J Hypertens 2008;21:674-8
162. Virdis A, Colucci R, Versari D, et al. Atorvastatin prevents endothelial dysfunction in mesenteric arteries from spontaneously hypertensive rats: role of cyclooxygenase 2-derived contracting prostanoids. Hypertension 2009;53:1008-16
163. Shechter M, Matetzky S, Arad M, et al. Vascular endothelial function predicts mortality risk in patients with advanced ischaemic chronic heart failure. Eur J Heart Fail 2009;11:588-93
164. Santos-Garcia D, Blanco M, Serena J, et al. Brachial arterial flow mediated dilation in acute ischemic stroke. Eur J Neurol 2009;16:684-90
165. Karatzis EN, Ikonomidis I, Vamvakou GD, et al. Long-term prognostic role of flow-mediated dilatation of the brachial artery after acute coronary syndromes without ST elevation. Am J Cardiol 2006;98:1424-8
166. Patti G, Pasceri V, Melfi R, et al. Impaired flow-mediated dilation and risk of restenosis in patients undergoing coronary stent implantation. Circulation 2005;111:70-5
167. Yeboah J, Folsom AR, Burke GL, et al. Predictive value of brachial flow-mediated dilation for incident cardiovascular events in a population-based study: the multi-ethnic study of atherosclerosis. Circulation 2009;120:502-9
168. Shechter M, Issachar A, Marai I, et al. Long-term association of brachial artery flow-mediated vasodilation and cardiovascular events in middle-aged subjects with no apparent heart disease. Int J Cardiol 2009;134:52-8
169. Suessenbacher A, Frick M, Alber HF, et al. Association of improvement of brachial artery flow-mediated vasodilation with cardiovascular events. Vasc Med 2006;11:239-44